|
||||||||||||||
Federal Tuberculosis Task Force Plan in Response to the Institute of Medicine Report, Ending Neglect: The Elimination of Tuberculosis in the United StatesReturn to Federal TB Task Force Plan Main Menu This is an archived document. The links and content are no longer being updated. Strategies and Action StepsDomestic Federal Actions in Response to the Institute
of Medicine Report on TB:
|
| Strategies |
Action Steps |
|---|---|
1. In collaboration with the World Health Organization (WHO), develop models for diagnosis and treatment of MDR TB in countries with high MDR TB rates. Lead Agencies: CDC, USAID Collaborating Agency: NIH Start Date: FY 2002 Completion Date: Ongoing |
a) Implement and expand model directly observed treatment, short course (DOTS) programs to prevent further creation of MDR TB caused by improper treatment of new TB patients.
b) Develop and implement pilot DOTS-Plus projects to treat existing MDR TB patients and prevent MDR TB.
c) Assist in the development of "Centers of Excellence" to ensure that MDR TB is addressed, to build high- grade local capacity, and to serve as regional training centers for professionals from other countries.
d) Evaluate the cost effectiveness and appropriate use of rapid methods for diagnosis of MDR TB.
e) Conduct drug resistance surveillance to measure the extent of MDR
TB and to determine
|
2. Provide international technical and programmatic assistance aimed at reducing the impact of TB globally. Lead Agencies: CDC, USAID, NIH Start Date: FY 2002 Completion Date: Ongoing |
a) Provide technical assistance to countries for TB surveillance.
b) Provide technical assistance to improve and enhance TB laboratory capabilities.
c) Develop and promote WHO/IUATLD/CDC national external quality assessment guidelines to monitor and improve the quality of AFB microscopy.
d) Conduct operational research to improve diagnosis and treatment of HIV-associated TB.
e) Conduct large-scale feasibility and cost-effectiveness studies of various regimens for the treatment of latent TB infection in HIV-infected persons.
f) Provide technical assistance for developing and implementing institutional infection control strategies.
g) Provide onsite technical assistance to national TB control programs.
|
3. Strengthen TB research capability in high-burden countries to enhance ability to develop and test improved treatment, prevention, and control strategies. Lead Agencies: CDC, NIH, USAID Collaborating Agency: None Start Date: FY 2002 |
a) Expand and conduct training and technology transfer in high-burden countries.
b) Enhance needed infrastructure, including laboratory facilities and Internet connectivity.
c) Conduct clinical trials of novel therapeutic, diagnostic, and prevention
strategies in
|
Last Reviewed: 05/18/2008
Content Source: Division of Tuberculosis Elimination
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
|
You will need Adobe Acrobat Reader v5.0 or higher to read pages that are in PDF format. Download the Adobe Acrobat Reader. If you have difficulty accessing any material on the DTBE Web site because of a disability, please contact us in writing or via telephone and we will work with you to make the information available. Division of Tuberculosis Elimination |
Home | Site Map
| Contact Us
Accessibility
| Privacy Policy Notice |
FOIA
| USA.gov
CDC Home |
Search |
Health Topics A-Z
Centers for Disease Control & Prevention
National Center for HIV/AIDS,
Viral Hepatitis, STD, and TB Prevention
Division of Tuberculosis Elimination
Please send comments/suggestions/requests to:
CDCINFO@cdc.gov